Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
about
The Gut Microbiota in Immune-Mediated Inflammatory DiseasesThe challenges, advantages and future of phenome-wide association studiesMultiple sclerosis: molecular mechanisms and therapeutic opportunitiesBiochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decadeMinocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo.Prospects for minocycline neuroprotection.Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition.Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis.Glatiramer acetate treatment negatively regulates type I interferon signaling.Minocycline: far beyond an antibiotic.A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndromeReduction of microglial activity in a model of multiple sclerosis by dipyridamole.11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats.Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.Approaches to neuroprotective strategies in multiple sclerosis.Immunomodulatory drug treatment in multiple sclerosis.Principles of a new treatment algorithm in multiple sclerosis.Neuroprotection in multiple sclerosis: a therapeutic approach.Disease modification in multiple sclerosis: an update.Influence of the Gut Microbiome on Autoimmunity in the Central Nervous System.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: a preliminary study.Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?Impact of Minocycline on Extracellular Matrix Metalloproteinase Inducer, a Factor Implicated in Multiple Sclerosis Immunopathogenesis.
P2860
Q26741414-2D99C2A9-83BA-43DE-9CE8-A60B33F045EBQ27023725-4BCBD9D6-FC49-43B7-9B8B-25A16B991828Q27023735-54EF414C-B213-4706-B686-6E9B1C23B4BBQ28288148-071F0021-B689-48E5-9323-907427A4B5EBQ34638224-BADA46E5-0039-4D92-908B-E437F80D0660Q35079515-23E52307-3A2F-4DEE-A354-6D0B2EA9A860Q35276622-69939542-B1CD-4DC7-9720-923DBC9A10B7Q35589934-ABA11691-F343-4D82-89A6-A7B152E7A0F5Q35840194-15881606-CF28-46D5-8263-6A9F71089B00Q36043123-3EABE5EC-B382-4698-918C-2C8C6EC30ED1Q36280868-BAC88E50-CBCB-4F92-B72D-8CD00775B871Q36836358-E40F6C90-125F-48D7-A675-B568B71AF563Q36996583-0B733F9E-CAFB-4E24-9DD1-66EF2FE8899BQ37048242-69707985-3F0F-4235-A530-78E6A5C3DE19Q37144048-1399D00D-5EAF-447B-8E22-DB0E63F073E8Q37676004-2C09B49A-DBE4-467A-B7BB-6659D3120380Q37778062-72CF52DA-AC33-4E0B-BB28-8E3F45B7B51CQ37785554-DC9B897B-0D78-4FE1-8024-35B19CE297F8Q37849763-44CCA192-1D61-4F81-9794-B760A21C63A5Q38129748-2238D9DB-6462-42D1-8CEE-462E50BE4D24Q38150823-82A65AC9-656E-40BB-BBDF-934D6BDF2CD2Q38772593-D74E2CDC-0B13-48F1-BE3F-727785451777Q38837294-2CFDBFBF-4044-4B0C-B42D-92D28228D672Q40020998-416E6332-3A1F-49A6-B484-22E57E385643Q42427291-C16F6059-3B1B-48D2-B0F5-E0718923A36CQ44887683-F380BEEE-77A1-40AB-AC8F-7C9081D8BE53Q48132838-8CD41009-B381-4CEC-943F-A437A4E06F1DQ48305463-41A1CB2F-3016-4DF3-9CA3-846C4D55AA69
P2860
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Glatiramer acetate in combinat ...... ind, placebo-controlled trial.
@ast
Glatiramer acetate in combinat ...... ind, placebo-controlled trial.
@en
type
label
Glatiramer acetate in combinat ...... ind, placebo-controlled trial.
@ast
Glatiramer acetate in combinat ...... ind, placebo-controlled trial.
@en
prefLabel
Glatiramer acetate in combinat ...... ind, placebo-controlled trial.
@ast
Glatiramer acetate in combinat ...... ind, placebo-controlled trial.
@en
P2093
P2860
P921
P356
P1476
Glatiramer acetate in combinat ...... ind, placebo-controlled trial.
@en
P2093
GA/minocycline study investigators
M Constantin
P Duquette
P2860
P304
P356
10.1177/1352458509106779
P577
2009-09-23T00:00:00Z